×

Message

Resource not found

News

Promoting access to health data for healthcare, research & policy-making 26-07-2021

 
Data_Space__1_.jpg

ESIP responds to the Public Consultation on the upcoming European Health Data Space

In view of the legislative proposal for a European Health Data Space (EHDS), expected by the end of this year, ESIP took part in the public consultation process on access to and exchange of health data for healthcare provision, policy-making and research & innovation purposes, as well as on the use of digital health products & services and development & deployment of AI systems applied to healthcare.

First insight into the revision of the EU pharma legislation 27-04-2021

 
Pharmaceuticals__2_2.jpg

ESIP responds to the evaluation roadmap-inception impact assessment

On 30 March the Commission launched the first stage of consultations with stakeholders towards the revision of the general pharmaceutical legislation, namely Directive 2001/83/EC1 and Regulation (EC) No 726/2004. ESIP submitted its first response to the evaluation roadmap-inception impact assessment touching upon several elements identified by the Commission to feed into future policy actions.

Promoting active & healthy ageing across the lifespan 20-04-2021

 
istockphoto-1008796894-612x612.jpg

ESIP responds to the Public Consultation on the Green Paper on Ageing

Social protection schemes in the EU are under strain as ageing increases demand for medical and long-term care (LTC) and old-age spendingIn this contextESIP provides its recommendations touching upon all branches of social security on how to tackle demographic change while fostering active and healthy ageing. 

 

3rd EMA-payer meeting on 12 March 2021 17-03-2021

 
3rd_EMA-payers_meeting_-_Agenda_-_Copy.png

Payers and EMA discussed evidence generation along the life-cycle of medicines

On 12 March, representatives from the European Social Insurance Platform (ESIP), the payer platform Medicines Evaluation Committee (MEDEV), the International Association of Mutual Benefit Societies (AIM) and the European Medicines Agency (EMA) met for the third time to further explore synergies and foster mutual understanding and cooperation on evidence generation, with the aim of better aligning evidence requirements for the different decision-making processes. On this occasion the focus was on evidence generation along the life-cycle of medicinal products.